The Research and Development (R&D) tax incentive encourages companies to engage in R&D and innovation, benefiting Australia, by providing a tax offset for eligible R&D activities.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Company Secretary and Investor Relations
FINANCE VIDEO: Regeneus Ltd (ASX:RGS) Interview with John Martin on Progenza and the Platform Technology